Sarepta Therapeutics Trading Volume Surges 335.89% to $536 Million Ranking 216th in Market Activity Despite Stock Price Decline

On July 24, 2025, Sarepta Therapeutics (SRPT) saw a significant increase in trading volume, reaching $536 million, a 335.89% rise from the previous day, ranking 216th in the day's stock market activity. However, the stock price of Sarepta Therapeutics (SRPT) fell by 3.30%, marking the second consecutive day of decline, with a total decrease of 5.40% over the past two days.

Sarepta Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for its gene therapy, SRP-9001, for the treatment of Duchenne muscular dystrophy (DMD). This approval is a significant milestone for Sarepta, as it represents the first gene therapy approved for DMD in the United States. The approval is based on positive results from clinical trials, which demonstrated the safety and efficacy of SRP-9001 in improving muscle function and reducing disease progression in DMD patients.

Sarepta Therapeutics has also announced that it has entered into a collaboration with a leading biotechnology company to develop and commercialize a new gene therapy for the treatment of another rare genetic disorder. The collaboration will leverage Sarepta's expertise in gene therapy and the partner's proprietary technology platform to develop a novel treatment for patients with this rare disease. The terms of the collaboration were not disclosed, but it is expected to accelerate the development and commercialization of the new gene therapy.

Sarepta Therapeutics has reported positive interim results from a Phase 1/2 clinical trial of its investigational gene therapy, SRP-9003, for the treatment of limb-girdle muscular dystrophy (LGMD). The results showed that SRP-9003 was well-tolerated and demonstrated promising efficacy in improving muscle function and reducing disease progression in LGMD patients. The company plans to initiate a Phase 3 clinical trial of SRP-9003 in the second half of 2025, subject to regulatory approval.